24 results on '"Brorson, K."'
Search Results
2. PDA/FDA Virus & TSE Safety Conference
- Author
-
Brorson, K., primary
- Published
- 2016
- Full Text
- View/download PDF
3. Meeting Report: 2015 PDA Virus & TSE Safety Forum
- Author
-
Willkommen, H., primary, Blumel, J., additional, Brorson, K., additional, Chen, D., additional, Chen, Q., additional, Groner, A., additional, Kreil, T. R., additional, Ruffing, M., additional, Ruiz, S., additional, Scott, D., additional, and Silvester, G., additional
- Published
- 2016
- Full Text
- View/download PDF
4. Proceedings of the 2013 Viral Clearance Symposium (Princeton, NJ)
- Author
-
Roush, D., primary, Brorson, K., additional, and Levy, R., additional
- Published
- 2015
- Full Text
- View/download PDF
5. Virus filtration: A review of current and future practices in bioprocessing.
- Author
-
Johnson SA, Chen S, Bolton G, Chen Q, Lute S, Fisher J, and Brorson K
- Subjects
- Animals, Biotechnology methods, Drug Contamination prevention & control, Filtration, Mammals, Virion, Viruses
- Abstract
For drug products manufactured in mammalian cells, safety assurance practices are needed during production to assure that the final medicinal product is safe from the potential risk of viral contamination. Virus filters provide viral retention for a range of viruses through robust, largely size-based retention mechanism. Therefore, a virus filtration step is commonly utilized in a well-designed recombinant therapeutic protein purification process and is a key component in an overall strategy to minimize the risks of adventitious and endogenous viral particles during the manufacturing of biotechnology products. This study summarizes the history of virus filtration, currently available virus filters and prefilters, and virus filtration integrity test methods and study models. There is also discussion of current understanding and gaps with an eye toward future trends and emerging filtration technologies., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
6. High Performance Size Exclusion Chromatography and High-Throughput Dynamic Light Scattering as Orthogonal Methods to Screen for Aggregation and Stability of Monoclonal Antibody Drug Products.
- Author
-
Bhirde A, Chikkaveeraiah BV, Venna R, Carley R, Brorson K, and Agarabi C
- Subjects
- Antibodies, Monoclonal, Chromatography, Gel, Dynamic Light Scattering, Antineoplastic Agents, Immunological, Pharmaceutical Preparations
- Abstract
The presence of aggregates in monoclonal antibody (mAb) drug product (DP) formulations can present product quality challenges. Here we show that use of High Performance Size Exclusion Chromatography (HP-SEC), in conjunction with high-throughput dynamic light scattering (HT-DLS) analyses of mAb DPs can be a useful strategy to determine monomer content and the presence of aggregates under simulated stress conditions. This analytical approach was used to evaluate four commercially available mAb DPs under different conditions i.e.; original formulations, diluted, and thermo-mechanical stressed condition. Due to particle size limitations of HP-SEC columns, resulting in particles accumulating in the column frits prior to reaching the detector for analysis, there is a possibility that large mAb aggregates may not be detected. Both HP-SEC and HT-DLS were able to detect and resolve the mAb monomer (~10-12 nm) of the DPs in their recommended storage conditions. However, the ability to detect large aggregates (>40 nm) by both analytical methods differed, and HT-DLS was able to detect aggregates between 60 nm and 1400 nm under stress conditions. Our data indicates that HP-SEC, in conjunction with HT-DLS, may be beneficial to detect both mAb DP monomer content and multiple aggregate species (1-1000 nm) in the submicron size range., (Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
7. Bioprocess: Robustness with Respect to Mycoplasma Species.
- Author
-
Faison T, Wang J, Johnson S, Brown M, Chiang MJ, Dolan S, Breuning C, Velugula-Yellela SR, Lute S, Fratz-Berilla EJ, and Brorson K
- Subjects
- Animals, CHO Cells, Coculture Techniques, Cricetinae, Cricetulus, Mycoplasma growth & development, Mycoplasma orale growth & development, Chemistry, Pharmaceutical methods, Drug Contamination prevention & control, Mycoplasma isolation & purification, Mycoplasma orale isolation & purification
- Abstract
Capture bioprocessing unit operations were previously shown to clear or kill several log
10 of a model mycoplasma Acholeplasma laidlawii in lab-scale spike/removal studies. Here, we confirm this observation with two additional mollicute species relevant to biotechnology products for human use: Mycoplasma orale and Mycoplasma arginini Clearance of M. orale and M. arginini from protein A column purification was similar to that seen with A. laidlawii , though some between cycle carryover was evident, especially for M. orale However, on-resin growth studies for all three species revealed that residual mycoplasma in a column slowly die off over time rather than expanding further. Solvent/detergent exposure completely inactivated M. arginini though detectable levels of M. orale remained. A small-scale model of a commercial low-pH hold step did inactivate live M. orale , but this inactivation required a lower pH set point and occurred with slower kinetics than previously seen with A. laidlawii Additionally, ultraviolet-C irradiation was shown to be effective for A. laidlawii and M. orale inactivation whereas virus-retentive filters for upstream and downstream processes, as expected, cleared A. laidlawii These data argue that M. orale and M. arginini overall would be largely cleared by early bioprocessing steps as shown previously for A. laidlawii, and that barrier technologies can effectively reduce the risk from media components. For some unit operations, M. orale and M. arginini may be hardier, and require more stringent processing or equipment cleaning conditions to assure effective mycoplasma reduction. By exploring how some of the failure modes in commercial antibody manufacturing processes can still eliminate mycoplasma burden, we demonstrate that required best practices assure biotechnology products will be safe for patients., (© PDA, Inc. 2020.)- Published
- 2020
- Full Text
- View/download PDF
8. The ELISA Detectability and Potency of Pegfilgrastim Decrease in Physiological Conditions: Key Roles for Aggregation and Individual Variability.
- Author
-
Xie T, Fang H, Ouyang W, Angart P, Chiang MJ, Bhirde AA, Sheikh F, Lynch P, Shah AB, Patil SM, Chen K, Shen M, Agarabi C, Donnelly RP, Brorson K, Schrieber SJ, Howard KE, Rogstad SM, and Frucht DM
- Subjects
- Animals, Cell Line, Tumor, Cell Proliferation, Enzyme-Linked Immunosorbent Assay standards, Humans, Mice, STAT3 Transcription Factor metabolism, Biological Variation, Individual, Filgrastim pharmacokinetics, Polyethylene Glycols pharmacokinetics
- Abstract
PEGylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) is used clinically to accelerate immune reconstitution following chemotherapy and is being pursued for biosimilar development. One challenge to overcome in pegfilgrastim biosimilar development is establishing pharmacokinetic (PK) similarity, which is partly due to the degree of PK variability. We herein report that commercially available G-CSF and PEG ELISA detection kits have different capacities to detect pegfilgrastim aggregates that rapidly form in vitro in physiological conditions. These aggregates can be observed using SDS-PAGE, size-exclusion chromatography, dynamic light scattering, and real-time NMR analysis and are associated with decreased bioactivity as reflected by reduced drug-induced cellular proliferation and STAT3 phosphorylation. Furthermore, individual variability in the stability and detectability of pegfilgrastim in human sera is also observed. Pegfilgrastim levels display marked subject variability in sera from healthy donors incubated at 37 °C. The stability patterns of pegfilgrastim closely match the stability patterns of filgrastim, consistent with a key role for pegfilgrastim's G-CSF moiety in driving formation of inactive aggregates. Taken together, our results indicate that individual variability and ELISA specificity for inactive aggregates are key factors to consider when designing and interpreting studies involving the measurement of serum pegfilgrastim concentrations.
- Published
- 2020
- Full Text
- View/download PDF
9. Impacts of intentional mycoplasma contamination on CHO cell bioreactor cultures.
- Author
-
Fratz-Berilla EJ, Faison T, Kohnhorst CL, Velugula-Yellela SR, Powers DN, Brorson K, and Agarabi C
- Subjects
- Animals, CHO Cells, Cricetulus, Bioreactors microbiology, Cell Culture Techniques, Equipment Contamination, Mycoplasma growth & development
- Abstract
Mycoplasma contamination events in biomanufacturing facilities can result in loss of production and costly cleanups. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and may penetrate the 0.2 µm filters often used in the primary clarification of harvested cell culture fluid. Culture cell-based and indicator cell-based assays that are used to detect mycoplasma are highly sensitive but can take up to 28 days to complete and cannot be used for real-time decision making during the biomanufacturing process. To support real-time measurements of mycoplasma contamination, there is a push to explore nucleic acid testing. However, cell-based methods measure growth or colony forming units and nucleic acid testing measures genome copy number; this has led to ambiguity regarding how to compare the sensitivity of the methods. In addition, the high risk of conducting experiments wherein one deliberately spikes mycoplasma into bioreactors has dissuaded commercial groups from performing studies to explore the multiple variables associated with the upstream effects of a mycoplasma contamination in a manufacturing setting. Here we studied the ability of Mycoplasma arginini to persist in a single-use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G1 (IgG1) antibody. We examined M. arginini growth and detection by culture methods, as well as the effects of M. arginini on mammalian cell health, metabolism, and productivity. We compared process parameters and controls normally measured in bioreactors including dissolved oxygen, gas mix, and base addition to maintain pH, to examine parameter changes as potential indicators of contamination. Our work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Importantly, how the M. arginini contamination impacts the CHO cells is influenced by the concentration of CHO cells and rate of perfusion at the time of M. arginini spike. Careful evaluation of dissolved oxygen, pH control parameters, ammonia, and arginine over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before a read-out from a traditional method., (© 2019 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
10. Multi-Attribute Method for Quality Control of Therapeutic Proteins.
- Author
-
Rogstad S, Yan H, Wang X, Powers D, Brorson K, Damdinsuren B, and Lee S
- Subjects
- Animals, Antibodies, Monoclonal chemistry, Humans, Quality Control, Chromatography, Liquid methods, Electrophoresis, Capillary methods, Mass Spectrometry methods, Peptides analysis, Proteins chemistry
- Abstract
Recent advances in high resolution mass spectrometry (MS) instrumentation and semi-automated software have led to a push toward the use of MS-based methods for quality control (QC) testing of therapeutic proteins in a cGMP environment. The approach that is most commonly being proposed for this purpose is known as the multi-attribute method (MAM). MAM is a promising approach that provides some distinct benefits compared to conventional methods currently used for QC testing of protein therapeutics, such as CEX, HILIC, and CE-SDS. Because MS-based methods have not been regularly used in this context in the past, new scientific and regulatory questions should be addressed prior to the final stages of implementation. We have categorized these questions into four major aspects for MAM implementation in a cGMP environment for both new and existing products: risk assessment, method validation, capabilities and specificities of the New Peak Detection (NPD) feature, and comparisons to conventional methods. This perspective outlines considerations for each of these main points and suggests approaches to help address potential issues.
- Published
- 2019
- Full Text
- View/download PDF
11. Validation and optimization of viral clearance in a downstream continuous chromatography setting.
- Author
-
Chiang MJ, Pagkaliwangan M, Lute S, Bolton G, Brorson K, and Schofield M
- Subjects
- Chromatography, Liquid, Humans, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal isolation & purification, Models, Chemical, Viruses chemistry
- Abstract
Continuous bioprocessing holds the potential to improve product consistency, accelerate productivity, and lower cost of production. However, switching a bioprocess from traditional batch to continuous mode requires surmounting business and regulatory challenges. A key regulatory requirement for all biopharmaceuticals is virus safety, which is assured through a combination of testing and virus clearance through purification unit operations. For continuous processing, unit operations such as capture chromatography have aspects that could be impacted by a change to continuous multicolumn operation, for example, do they clear viruses as well as a traditional batch single column. In this study we evaluate how modifying chromatographic parameters including the linear velocity and resin capacity utilization could impact virus clearance in the context of moving from a single column to multicolumn operation. A Design of Experiment (DoE) approach was taken with two model monoclonal antibodies (mAbs) and two bacteriophages used as mammalian virus surrogates. The DoE enabled the identification of best and worst-case scenario for virus clearance overall. Using these best and worst-case conditions, virus clearance was tested in single column and multicolumn modes and found to be similar as measured by Log Reduction Values (LRV). The parameters identified as impactful for viral clearance in single column mode were predictive of multicolumn modes. Thus, these results support the hypothesis that the viral clearance capabilities of a multicolumn continuous Protein A system may be evaluated using an appropriately scaled-down single mode column and equipment., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
12. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
- Author
-
Fisher AC, Kamga MH, Agarabi C, Brorson K, Lee SL, and Yoon S
- Subjects
- Biotechnology trends, Technology, Pharmaceutical trends, Biological Products isolation & purification, Biological Products metabolism, Biotechnology methods, Drug Approval methods, Technology, Pharmaceutical methods
- Abstract
There is a trend across the pharmaceutical sector toward process intensification and continuous manufacturing to produce small-molecule drugs or biotechnology products. For biotechnology products, advancing the manufacturing technology behind upstream and downstream processes has the potential to reduce product shortages and variability, allow for production flexibility, simplify scale-up procedures, improve product quality, reduce facility footprints, increase productivity, and reduce production costs. On the upstream side of biotechnology manufacturing, continuous perfusion cell cultures are fairly well established. However, truly integrated continuous biomanufacturing requires the uninterrupted connection of continuous unit operations (upstream and downstream) with no isolated intermediate or hold steps occurring between them. This work examines the current scientific and regulatory landscape surrounding the implementation of integrated continuous biomanufacturing., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. An ICP-MS platform for metal content assessment of cell culture media and evaluation of spikes in metal concentration on the quality of an IgG3:κ monoclonal antibody during production.
- Author
-
Mohammad A, Agarabi C, Rogstad S, DiCioccio E, Brorson K, Ashraf M, Faustino PJ, and Madhavarao CN
- Subjects
- Animals, Antibodies, Monoclonal genetics, Bioreactors, CHO Cells, Cell Proliferation, Cricetulus, Glucuronidase genetics, Glycosylation, Hybridomas, Immunoglobulin G genetics, Immunoglobulin kappa-Chains genetics, Mass Spectrometry standards, Mice, Quality Control, Reproducibility of Results, Time Factors, Transfection, Antibodies, Monoclonal biosynthesis, Copper metabolism, Culture Media metabolism, Glucuronidase biosynthesis, Immunoglobulin G biosynthesis, Immunoglobulin kappa-Chains biosynthesis, Iron metabolism, Mass Spectrometry methods
- Abstract
Metal ions can be enzyme cofactors and can directly influence the kinetics of biochemical reactions that also influence the biological production and quality attributes of therapeutic proteins, such as glycan formation and distribution. However, the concentrations of metals in commercially available chemically defined media can range from 1 to 25,000 ppb. Because such concentration changes can impact cell growth, manufacturing yield and product quality the alteration/fluctuation in media composition should be well controlled to maintain product quality. Here, we describe a platform of analytical methods to determine the composition of several metals in different sample matrices using an advanced automated Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). These methods, validated to ICH Q2R1 regulatory validation parameters, were successfully applied to- (a) screen cell culture media; (b) determine changes in the metal concentration during cell growth in spinner flasks, and, (c) determine effect on the glycosylation pattern and homogeneity of an IgG3:κ produced from a murine-hybridoma cell line in bench-top parallel bioreactors due to a spike in copper and iron concentration. Our results show that maintenance of metal content in the cell culture media is critical for product consistency of the IgG3:κ produced., (Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF
14. High-Throughput In-Use and Stress Size Stability Screening of Protein Therapeutics Using Algorithm-Driven Dynamic Light Scattering.
- Author
-
Bhirde AA, Chiang MJ, Venna R, Beaucage S, and Brorson K
- Subjects
- Algorithms, Drug Stability, Humans, Particle Size, Protein Aggregates, Protein Stability, Temperature, Antibodies, Monoclonal chemistry, Dynamic Light Scattering methods, Pharmaceutical Preparations chemistry, Proteins chemistry
- Abstract
Stability of therapeutic proteins (TPs) is a critical quality attribute that impacts both safety and efficacy of the drug. Size stability is routinely performed during and after biomanufacturing. Dynamic light scattering (DLS) is a commonly used technique to characterize hydrodynamic size of the TPs. Herein, we have developed a novel method to evaluate in-use and thermal stress stability of TPs using algorithm-driven high-throughput DLS. Five marketed TPs were tested under the guidance of customized algorithms. The TPs were evaluated at relevant temperature conditions as well as under dilution and thermal stress for size stability. We found that the TPs were stable under the in-use conditions tested; however, sample loss due to evaporation can lead to large protein aggregates. A combined assessment of autocorrelation function and photos of sample well could be useful in formulation screening. Dilution of TPs also has an impact on the hydrodynamic size. Thermal stress experiments showed the importance of using different data processing methods to access size distribution. Polydispersity index was useful in evaluating sample heterogeneity. Herein, we show that algorithm-driven high-throughput DLS can provide additional supportive information during and after biomanufacturing and the potential to be used in a quality control environment., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
15. Farewell and Thanks!
- Author
-
Brorson K, Junker B, Moreira A, Rathore A, Ricci M, and Rao G
- Subjects
- Humans, Periodicals as Topic, Technology, Pharmaceutical
- Published
- 2018
- Full Text
- View/download PDF
16. Comparison of purification strategies for antibodies used in a broad spectrum host cell protein immunoassay.
- Author
-
Baldus PA, Brown M, Wright RS, Campbell JA, Lute S, Chavez B, Brorson K, and Mozier N
- Subjects
- Animals, Antibodies analysis, Antibodies chemistry, Biotechnology, CHO Cells, Cricetinae, Cricetulus, Proteins chemistry, Antibodies isolation & purification, Blotting, Western methods, Chromatography, Affinity methods, Enzyme-Linked Immunosorbent Assay methods
- Abstract
Host cell proteins (HCPs) are a heterogeneous mixture of impurities that should be minimized in bulk preparations of biotechnologically produced medicines. Immunoassays are commonly used to detect and measure HCPs in therapeutic products, and a successful assay is directly dependent on the quality of the polyclonal antibodies (pAbs) used. These pAbs are enriched from antisera of animals immunized with a broad mixture of HCPs, but there is limited information regarding the best strategy for purification of these critical reagents. The use of protein A or protein G affinity chromatography results in purified pAbs that are not entirely HCP-specific, while the use of HCP affinity chromatography results in a more specific pAb population but may be harder to recover fully. In theory, both approaches have advantages and disadvantages for generating optimal reagents. In this study, we compared reagents from these two purification procedures using the same starting material, as well as those from a step-wise combination of the two by evaluating purity, concentration, reagent coverage by Western blotting, and performance in an enzyme-linked immunosorbent assay (ELISA). This study demonstrates that pAbs purified by each of the methods are very similar in terms of sensitivity, the ability to recognize a broad range of HCPs, and overall performance in an ELISA measuring a range of HCPs in upstream process and final drug substance (DS) samples., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
17. Mycoplasma Clearance and Risk Analysis in a Model Bioprocess.
- Author
-
Wang J, Johnson S, Brown M, Lute S, Agarabi C, Dabrazhynetskaya A, Chizhikov V, and Brorson K
- Subjects
- Acholeplasma laidlawii growth & development, Animals, Bacteriological Techniques methods, Biotechnology methods, CHO Cells, Cricetulus, Kinetics, Mycoplasma growth & development, Quality Control, Risk Assessment, Acholeplasma laidlawii isolation & purification, Bacteriological Techniques standards, Biotechnology standards, Drug Contamination prevention & control, Models, Theoretical, Mycoplasma isolation & purification
- Abstract
Mycoplasmas are a type of bacteria that lack cell walls and are occasional cell culture contaminants. In a biotechnology setting, because they can pass through 0.2 μm filters, mycoplasmas could pose a potential patient safety hazard if undetected contaminants from the production culture were not completely removed by downstream biotechnology manufacturing. In this study we investigated the ability of typical commercial monoclonal antibody purification operations to clear and kill mycoplasmas, using Acholeplasma laidlawii as a model organism. Our spike/removal studies have shown that protein A column chromatography clears about 4-5 log
10 Column regeneration effectively prevents A. laidlawii column carryover between chromatography runs. Moreover, low-pH hold steps, typically implemented after protein A purification, effectively kill A. laidlawii using either pH 3.8 glycine or acetate solutions (LRV ≥5.30 and ≥4.57, respectively). Solvent/detergent treatment, used in some processes instead of low-pH hold, also completely kills highly concentrated A. laidlawii (LRV ≥5.95). LAY ABSTRACT: Biotechnology medicines need to be free from contaminating microorganisms such as mycoplasmas, a type of bacteria that can cause disease in humans (e.g., walking pneumonia). Here we show that some monoclonal antibody manufacturing steps can effectively clear and/or kill Acholeplasma laidlawii , a model mycoplasma species used in our study. This provides an additional level of safety assurance of biotechnology medicines for patients., (© PDA, Inc. 2017.)- Published
- 2017
- Full Text
- View/download PDF
18. Emerging Technology as a Key Enabler for Modernizing Pharmaceutical Manufacturing.
- Author
-
Lee SL and Brorson K
- Subjects
- Drug Industry trends, Humans, Technology, Pharmaceutical trends, Drug Industry standards, Pharmaceutical Preparations standards, Quality Control, Technology, Pharmaceutical standards
- Published
- 2017
- Full Text
- View/download PDF
19. A design space exploration for control of Critical Quality Attributes of mAb.
- Author
-
Bhatia H, Read E, Agarabi C, Brorson K, Lute S, and Yoon S
- Subjects
- Animals, Data Interpretation, Statistical, Immunoglobulin G chemistry, Mice, Polysaccharides chemistry, Antibodies, Monoclonal chemistry, Chemistry, Pharmaceutical methods, Models, Theoretical, Quality Control, Technology, Pharmaceutical methods
- Abstract
A unique "design space (DSp) exploration strategy," defined as a function of four key scenarios, was successfully integrated and validated to enhance the DSp building exercise, by increasing the accuracy of analyses and interpretation of processed data. The four key scenarios, defining the strategy, were based on cumulative analyses of individual models developed for the Critical Quality Attributes (23 Glycan Profiles) considered for the study. The analyses of the CQA estimates and model performances were interpreted as (1) Inside Specification/Significant Model (2) Inside Specification/Non-significant Model (3) Outside Specification/Significant Model (4) Outside Specification/Non-significant Model. Each scenario was defined and illustrated through individual models of CQA aligning the description. The R(2), Q(2), Model Validity and Model Reproducibility estimates of G2, G2FaGbGN, G0 and G2FaG2, respectively, signified the four scenarios stated above. Through further optimizations, including the estimation of Edge of Failure and Set Point Analysis, wider and accurate DSps were created for each scenario, establishing critical functional relationship between Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs). A DSp provides the optimal region for systematic evaluation, mechanistic understanding and refining of a QbD approach. DSp exploration strategy will aid the critical process of consistently and reproducibly achieving predefined quality of a product throughout its lifecycle., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
20. Hybridoma cell-culture and glycan profile dataset at various bioreactor conditions.
- Author
-
Bhatia H, Read E, Agarabi C, Brorson K, Lute S, and Yoon S
- Abstract
This is an "11 factor-2 level-12 run" Plackett-Burman experimental design dataset. The dataset includes 11 engineering bioreactor parameters as input variables. These 11 factors were varied at 2 levels and 23 response variables that are glycan profile attributes, were measured "A Design Space Exploration for Control of Critical Quality Attributes of mAb" (H. Bhatia, E.K. Read, C.D. Agarabi, K.A. Brorson, S.C. Lute, S. Yoon S, 2016) [2].
- Published
- 2016
- Full Text
- View/download PDF
21. N-Glycosylation Design and Control of Therapeutic Monoclonal Antibodies.
- Author
-
Sha S, Agarabi C, Brorson K, Lee DY, and Yoon S
- Subjects
- Animals, CHO Cells, Cell Line, Cricetinae, Cricetulus, Glycosylation, Humans, Mice, Polysaccharides chemistry, Polysaccharides genetics, Polysaccharides metabolism, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal genetics, Antibodies, Monoclonal metabolism, Glycoproteins chemistry, Glycoproteins genetics, Glycoproteins metabolism, Metabolic Engineering, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism
- Abstract
The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly affect antibody biological functions and are largely determined by host cell genotypes and culture conditions. A key step in bioprocess development for monoclonal antibodies (mAbs) involves optimization and control of N-glycan profiles. With pressure from pricing and biosimilars looming, more efficient and effective approaches are sought in the field of glycoengineering. Metabolic studies and mathematical modeling are two such approaches that optimize bioprocesses by better understanding and predicting glycosylation. In this review, we summarize a group of strategies currently used for glycan profile modulation and control. Metabolic analysis and mathematical modeling are then explored with an emphasis on how these two techniques can be utilized to advance glycoengineering., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
22. Mechanistic failure mode investigation and resolution of parvovirus retentive filters.
- Author
-
LaCasse D, Lute S, Fiadeiro M, Basha J, Stork M, Brorson K, Godavarti R, and Gallo C
- Subjects
- Filtration, Hydrodynamics, Particle Size, Virion chemistry, Parvovirus isolation & purification, Virion isolation & purification
- Abstract
Virus retentive filters are a key product safety measure for biopharmaceuticals. A simplistic perception is that they function solely based on a size-based particle removal mechanism of mechanical sieving and retention of particles based on their hydrodynamic size. Recent observations have revealed a more nuanced picture, indicating that changes in viral particle retention can result from process pressure and/or flow interruptions. In this study, a mechanistic investigation was performed to help identify a potential mechanism leading to the reported reduced particle retention in small virus filters. Permeate flow rate or permeate driving force were varied and analyzed for their impact on particle retention in three commercially available small virus retentive filters. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:959-970, 2016., (© 2016 American Institute of Chemical Engineers.)
- Published
- 2016
- Full Text
- View/download PDF
23. Development of a modular virus clearance package for anion exchange chromatography operated in weak partitioning mode.
- Author
-
Iskra T, Sacramo A, Gallo C, Godavarti R, Chen S, Lute S, and Brorson K
- Subjects
- Animals, Antibodies, Monoclonal isolation & purification, Bacteriophages isolation & purification, CHO Cells, Cricetulus, Hydrogen-Ion Concentration, Molecular Weight, Chromatography, Ion Exchange methods, Parvovirus isolation & purification, Retroviridae isolation & purification
- Abstract
Anion exchange chromatography (AEX) operated under weak partitioning mode has been proven to be a powerful polishing step as well as a robust viral clearance step in Pfizer's monoclonal antibody (mAb) platform purification process. A multivariate design of experiment (DoE) study was conducted to understand the impact of operating parameters and feedstream impurity levels on viral clearance by weak partitioning mode AEX. Bacteriophage was used initially as a surrogate for neutral and acidic isoelectric point mammalian viruses (e.g., retrovirus and parvovirus). Five different mAbs were used in the evaluation of process parameters such as load challenge (both product and impurities), load pH, load conductivity, and contact time (bed height and flow-rate). The operating ranges obtained from phage clearance studies and Pfizer's historical data were used to define an appropriate operating range for a subsequent clearance study with model retrovirus and parvovirus. Both phage and virus clearance evaluations included feedstreams containing different levels of impurities such as high molecular mass species (HMMS), host cell proteins (HCPs), and host cell DNA. For all the conditions tested, over 5 log10 of clearance for both retrovirus and parvovirus was achieved. The results demonstrated that weak partitioning mode AEX chromatography is a robust step for viral clearance and has the potential to be included as part of the modular viral clearance approach., (© 2015 American Institute of Chemical Engineers.)
- Published
- 2015
- Full Text
- View/download PDF
24. Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality.
- Author
-
Brorson K and Jia AY
- Subjects
- Animals, Antibodies, Monoclonal isolation & purification, Antibodies, Monoclonal therapeutic use, Drug Storage, Glutamic Acid metabolism, Protein Isoforms chemistry, Protein Isoforms isolation & purification, Protein Isoforms therapeutic use, Pyrrolidonecarboxylic Acid metabolism, Antibodies, Monoclonal chemistry, Biotechnology, Protein Processing, Post-Translational
- Abstract
Monoclonal antibodies (mAbs) are biological macromolecules with complex post-translational modifications that can be observed when assessing product variants. The N- and C-terminal heterogeneities of commercially produced antibodies have been observed and extensively studied over the past 30 years. This review summarizes the current literature on detectable antibody termini variants from cultured cells. The presence of these heterogeneities can be detected by many different analytical methods, mostly based on sequence, charge and size differences. Examples are presented that highlight terminal heterogeneities, methods of detection, and their impact on the quality of mAbs. Regulatory considerations are also discussed regarding the potential impact on product quality, safety, and efficacy., (Published by Elsevier Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.